spacer
The Healthcare Sales & Marketing Network celebrates 27 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  von Willebrand Factor 

 HSMN NewsFeed - 19 Jun 2024
European Commission grants Sobi(R) Marketing Authorisation for ALTUVOCT(TM) for treatment of haemophilia A
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 26 Apr 2024
Sobi(R) Receives Positive CHMP Opinion Recommending Approval of Efanesoctocog Alfa for Once-Weekly Treatment of Haemophilia A
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 24 Feb 2023
FDA approves once-weekly efanesoctocog alfa, a new class of high-sustained factor VIII therapy for haemophilia A: Swedish Orphan Biovitrum AB
Biopharmaceuticals FDA
 HSMN NewsFeed - 24 Feb 2022
Artio Medical Welcomes New R&D Leaders and Accelerates Development of Amplifi(TM) Vein Dilation System
Devices Personnel
 HSMN NewsFeed - 3 Sep 2018
Cablivi(TM) (caplacizumab) approved in Europe for adults with acquired thrombotic thrombocytopenic purpura (aTTP)
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 28 Jul 2015
U.S. FDA Accepts for Review CSL Behring's Biologics License Application for Its Novel rVIII-SingleChain Therapy for Patients with Hemophilia A
Biopharmaceuticals FDA
 HSMN NewsFeed - 9 Aug 2010
Pfizer Receives FDA Approval for Prefilled Dual-Chamber Syringe for Use in the Treatment of Hemophilia A
Biopharmaceuticals Drug Delivery FDA
 HSMN NewsFeed - 13 Jan 2010
Octapharma Receives Orphan Drug Exclusivity Approval for wilate(R) - A Replacement Therapy Developed Specifically for von Willebrand Disease
Biopharmaceuticals FDA
 HSMN NewsFeed - 7 Dec 2009
Octapharma USA Announces FDA Approval of wilate(R) - the First Replacement Therapy Developed Specifically for von Willebrand Disease
Biopharmaceuticals FDA
 HSMN NewsFeed - 27 Jan 2009
Archemix Announces Continued Progress with Business Strategy
Biopharmaceuticals Personnel
 HSMN NewsFeed - 8 Sep 2008
New Recombinant XYNTHA Now Available for Patients with Hemophilia A
Biopharmaceuticals
 HSMN NewsFeed - 22 Apr 2008
Archemix' ARC1779 Granted Orphan Designation for the Treatment of TTP, a Life-Threatening Blood Disorder
Biopharmaceuticals FDA
 HSMN NewsFeed - 21 Feb 2008
Wyeth's XYNTHA Approved by FDA for Treatment of Hemophilia A
Biopharmaceuticals FDA
 HSMN NewsFeed - 19 Dec 2007
CSL Behring Expands Into Middle East Market with Haemate(R) P
Biopharmaceuticals
 HSMN NewsFeed - 30 Apr 2007
Humate-P(R) Approved to Prevent Excessive Bleeding in Patients with von Willebrand Disease Undergoing Surgery
Biopharmaceuticals FDA
 HSMN NewsFeed - 1 Feb 2007
CSL Behring and Bayer Extend Agreement for Supply of Helixate(R) Recombinant Coagulation Factor
Biopharmaceuticals Licensing Distribution
 HSMN NewsFeed - 1 Feb 2007
Grifols Announces FDA Approval of Alphanate(R) to Treat von Willebrand Disease
Biopharmaceuticals FDA
 HSMN NewsFeed - 28 Nov 2006
Ciphergen and Ohio State University Research Foundation Sign Collaborative Agreement to Develop Diagnostic Test for Blood Disorder
Diagnostics
 HSMN NewsFeed - 3 Oct 2006
Archemix Strengthens Management With Appointment of James Gilbert, M.D., as Chief Medical Officer
Biopharmaceuticals Personnel
Return to NewsFeed  

 Additional items found! 3

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 3 additional stories matching:
von Willebrand Factor
(Password required)
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.